Bexion Pharmaceuticals
Wednesday, June 05, 2024
Oncology
Company Presentation Theater 1
Bexion Pharmaceuticals is a biotechnology company developing biologics targeting sphingolipid metabolism for the treatment of solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). Lead asset BXQ-350 modulates sphingolipid metabolism, increasing the ratio of certain ceramides to S1P in dysregulated cells, allowing for programmed cell death, reduced proliferation, and immune stimulation.
Company Website:
https://www.bexionpharma.com/
Lead Product in Development:
BXQ-350 - An innovative asset with potential for multiple indications. BXQ-350 is a lipid nanovesicle of Saposin C, a protein that activates sphingolipid metabolism to increase ceramides and reduce S1P. Ceramides and S1P are key therapeutic targets in CRC that impact survival.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Covington
Company HQ State
KY
Company HQ Country
United States
CEO/Top Company Official
Scott Shively - CEO
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())